Hydron Technologies, Inc. Adds Clinical and Regulatory Consultants, Plans to Seek FDA Approval for Wound Care Oxygenation Technology POMPANO BEACH, Fla., Feb. 10 /PRNewswire-FirstCall/ -- Hydron Technologies, Inc. (BULLETIN BOARD: HTEC) announced it has added expert clinical and regulatory consultants and will pursue approval from the FDA to allow the use of its oxygenation technology for a number of medical applications. Hydron has developed and received a U.S. patent for the method of oxygenating skin and tissue topically, using microbubbles of pure oxygen suspended in fluid. This technology has important medical applications for improving medical treatments and quality of life for burn victims, chronic wound care, radiation induced injury, decubitus and pressure ulcers (bed sores), skin grafts and frostbite. Hydron has added two senior-level consultants to help structure the volumes of supporting materials and experimental results required by the FDA for approval of the new technology: Dr. Len Rosenberg -- Managing partner at eP2Consulting, Inc., a consulting firm focused on strategic clinical and regulatory solutions in the drug and device development space for small to mid-size bio-pharmaceutical companies. Dr. Judy Gordon -- Managing partner at ClinReg Consulting Services, Inc., a clinical and regulatory consulting group primarily focusing in device development. Dr. Gordon has successfully attained FDA approval for more than 10 original PMAs for Class III devices. According to Richard Banakus, Hydron Technologies' CEO, "We believe the company has a significant innovation to offer to the medical community. Hydron's technology delivers the oxygen partial pressure of full hyperbaric treatments to the surface of the skin in a simple, convenient liquid form, while also avoiding the expense of hyperbaric chambers. Ultimately this technology should allow for treatment of patients at home." According to Dr. Rosenberg, "Within the FDA, it is not the use of oxygen that is regulated, rather, the FDA regulates the devices and means by which the oxygen is delivered to tissue. The mechanism of oxygen's role in wound healing is well understood and there are a number of indications where oxygen is a significant adjunct to a wide variety of wound healing applications. Hydron's microbubble-laden fluids have been shown to penetrate tissue to depths in experimental models that should provide significant patient benefits." Dr. Gordon stated, "I am pleased to be working on a project that has the potential to expand oxygen therapy for wounds, making it more convenient and accessible to a significantly broader range of patients." Banakus added, "Hydron recently completed a private placement offering, raising $1.1 million, to accelerate itsresearch and development program surrounding this technology. Now, with the addition of these new consultants and the development of a plan to approach the FDA, Hydron is furthering its shift into becoming a medical technology company." Hydron Technologies, Inc. is expanding its research and development of products and medical applications associated with its proprietary tissue oxygenation technology. The Company also markets skin care products through Hydron's direct-to-consumer catalog and on the Internet at http://www.hydron.com/. Catalogs are available by calling 1-800-4-HYDRON (1-800-449-3766). Except for historical information, all of the expectations and assumptions contained in the foregoing are forward-looking statements involving risks and uncertainties. For additional information regarding the risks associated with the Company's business, refer to Hydron Technologies, Inc. reports filed with the SEC. DATASOURCE: Hydron Technologies, Inc. CONTACT: Terrence S. McGrath, Chief Operating Officer, Hydron Technologies, +1-954-861-6416, or Web site: http://www.hydron.com/

Copyright